OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire‐Alvarez, А. В. Амелин, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1937-1958
Open Access | Times Cited: 38
Jason Aldred, Eric Freire‐Alvarez, А. В. Амелин, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1937-1958
Open Access | Times Cited: 38
Showing 1-25 of 38 citing articles:
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, et al.
Clinical Parkinsonism & Related Disorders (2024) Vol. 10, pp. 100239-100239
Open Access | Times Cited: 9
Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, et al.
Clinical Parkinsonism & Related Disorders (2024) Vol. 10, pp. 100239-100239
Open Access | Times Cited: 9
Levodopa Pharmacokinetics in Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient with Parkinson's Disease: a case report
Tomonori Nukariya, Toshiki Tezuka, Shohei Okusa, et al.
Journal of Movement Disorders (2025)
Open Access | Times Cited: 1
Tomonori Nukariya, Toshiki Tezuka, Shohei Okusa, et al.
Journal of Movement Disorders (2025)
Open Access | Times Cited: 1
Neutrophil‐Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa
David Weise, Sebastian Haferkamp
Movement Disorders (2025)
Open Access | Times Cited: 1
David Weise, Sebastian Haferkamp
Movement Disorders (2025)
Open Access | Times Cited: 1
Invasive therapies for Parkinson’s disease: an adapted excerpt from the guidelines of the German Society of Neurology
René Reese, Thomas Koeglsperger, Christoph Schrader, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Open Access | Times Cited: 1
René Reese, Thomas Koeglsperger, Christoph Schrader, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Open Access | Times Cited: 1
Subcutaneous Levodopa: A New Engine for the Vintage Molecule
Karolina Popławska-Domaszewicz, Lucia Batzu, Cristian Falup‐Pecurariu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1055-1068
Open Access | Times Cited: 7
Karolina Popławska-Domaszewicz, Lucia Batzu, Cristian Falup‐Pecurariu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1055-1068
Open Access | Times Cited: 7
Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook
Mickael Aubignat, Mélissa Tir
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 10, pp. 1188-1194
Open Access | Times Cited: 7
Mickael Aubignat, Mélissa Tir
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 10, pp. 1188-1194
Open Access | Times Cited: 7
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Nils Schröter, Bastian Sajonz, Wolfgang H. Jost, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 11, pp. 1285-1293
Open Access | Times Cited: 5
Nils Schröter, Bastian Sajonz, Wolfgang H. Jost, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 11, pp. 1285-1293
Open Access | Times Cited: 5
What was first and what is next in selecting device-aided therapy in Parkinson’s disease? Balancing evidence and experience
Onanong Phokaewvarangkul, Manon Auffret, Sergiu Groppa, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 11, pp. 1307-1320
Closed Access | Times Cited: 5
Onanong Phokaewvarangkul, Manon Auffret, Sergiu Groppa, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 11, pp. 1307-1320
Closed Access | Times Cited: 5
How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis
Katarzyna Śmiłowska, Vanessa Carvalho, Natalia Szejko, et al.
European Journal of Neurology (2025) Vol. 32, Iss. 1
Closed Access
Katarzyna Śmiłowska, Vanessa Carvalho, Natalia Szejko, et al.
European Journal of Neurology (2025) Vol. 32, Iss. 1
Closed Access
Reply to: “Neutrophil‐Rich Infusion Site Reactions after Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa”
Nagisa Yoshihara, Rei Watanabe, Noriko Nishikawa, et al.
Movement Disorders (2025)
Open Access
Nagisa Yoshihara, Rei Watanabe, Noriko Nishikawa, et al.
Movement Disorders (2025)
Open Access
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations
Thomas Koeglsperger, Emir Berberovic, Christian Dresel, et al.
Journal of Neural Transmission (2025)
Open Access
Thomas Koeglsperger, Emir Berberovic, Christian Dresel, et al.
Journal of Neural Transmission (2025)
Open Access
Managing impulse control and related behavioral disorders in Parkinson’s disease: where we are in 2025?
Leonardo Rigon, Carmelo Fogliano, К. Ray Chaudhuri, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Leonardo Rigon, Carmelo Fogliano, К. Ray Chaudhuri, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa
К. Ray Chaudhuri, Maurizio Facheris, Bruno Bergmans, et al.
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 7, pp. 861-866
Open Access | Times Cited: 4
К. Ray Chaudhuri, Maurizio Facheris, Bruno Bergmans, et al.
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 7, pp. 861-866
Open Access | Times Cited: 4
Surgical Treatments of Parkinson’s Disease
Ariane Veilleux Carpentier, Michael S. Okun
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 383-397
Closed Access
Ariane Veilleux Carpentier, Michael S. Okun
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 383-397
Closed Access
Therapeutic innovations for the symptomatic treatment of Parkinson’s disease: focus on technology-based therapies
Jeryl Ritzi T. Yu, Avery Kundrick, Enrique C. Panganiban, et al.
Journal of Neural Transmission (2025)
Closed Access
Jeryl Ritzi T. Yu, Avery Kundrick, Enrique C. Panganiban, et al.
Journal of Neural Transmission (2025)
Closed Access
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Hannah A. Blair
CNS Drugs (2025)
Closed Access
Hannah A. Blair
CNS Drugs (2025)
Closed Access
Parkinson’s Disease: New Therapeutic Developments from L-DOPA to Digital Therapies
Francesco Ferrara
SN Comprehensive Clinical Medicine (2025) Vol. 7, Iss. 1
Closed Access
Francesco Ferrara
SN Comprehensive Clinical Medicine (2025) Vol. 7, Iss. 1
Closed Access
Levodopa infusion therapies for Parkinson disease
Marissa Dean, David G. Standaert
Current Opinion in Neurology (2024) Vol. 37, Iss. 4, pp. 409-413
Closed Access | Times Cited: 3
Marissa Dean, David G. Standaert
Current Opinion in Neurology (2024) Vol. 37, Iss. 4, pp. 409-413
Closed Access | Times Cited: 3
Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction
Silvia Giménez, Alexandra Millan, Alba Mora-Morell, et al.
Molecules (2024) Vol. 29, Iss. 15, pp. 3580-3580
Open Access | Times Cited: 3
Silvia Giménez, Alexandra Millan, Alba Mora-Morell, et al.
Molecules (2024) Vol. 29, Iss. 15, pp. 3580-3580
Open Access | Times Cited: 3
Parkinson’s Kinetigraph for Wearable Sensor Detection of Clinically Unrecognized Early-Morning Akinesia in Parkinson’s Disease: A Case Report-Based Observation
Karolina Popławska-Domaszewicz, Naomi Limbachiya, Yue Hui Lau, et al.
Sensors (2024) Vol. 24, Iss. 10, pp. 3045-3045
Open Access | Times Cited: 2
Karolina Popławska-Domaszewicz, Naomi Limbachiya, Yue Hui Lau, et al.
Sensors (2024) Vol. 24, Iss. 10, pp. 3045-3045
Open Access | Times Cited: 2
Advances in Brain Stimulation and Nanomedicine: Dopaminergic Alterations and Its Role in Neurodegeneration and Drug Addiction
S. GIMENEZ, Alexandra Millan, Alba Mora-Morell, et al.
(2024)
Open Access | Times Cited: 2
S. GIMENEZ, Alexandra Millan, Alba Mora-Morell, et al.
(2024)
Open Access | Times Cited: 2
Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson’s disease
William L. Murch, John Spiridigliozzi, Adam Heller, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
William L. Murch, John Spiridigliozzi, Adam Heller, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa‐Foscarbidopa Hydrate: Histopathology
Nagisa Yoshihara, Noriko Nishikawa, Rei Watanabe, et al.
Movement Disorders (2024)
Open Access | Times Cited: 2
Nagisa Yoshihara, Noriko Nishikawa, Rei Watanabe, et al.
Movement Disorders (2024)
Open Access | Times Cited: 2
Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson’s disease patients
Szabolcs Szatmári, József Attila Szász, Károly Orbán-Kis, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Szabolcs Szatmári, József Attila Szász, Károly Orbán-Kis, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
